Business
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of the Company's human epidermal growth factor receptor 2 (HER2)-directed ADC trastuzumab botidotin (also known as A166) trastuzumab botidotin versus trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic BC was presented as an oral report by Professor Xichun Hu from Fudan Univer
About this update from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
[{"type":"text","content":"CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of the Company's human epidermal growth factor receptor 2 (HER2)-directed ADC trastuzumab botidotin (also known as A166) trastuzumab botidotin versus trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic BC was presented as an oral report by Professor Xichun Hu from Fudan University Shanghai Cancer Center (Presentation # LBA24, Proffered paper session 1: Breast cancer, metastatic).","length":670,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":212,"url":"https://media.zenfs.com/en/prnewswire.com/2b76d4ebfc4f3481167aa205dbe9c5e1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SWJSwl.G8jJRDt5EY4bF2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM3NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2b76d4ebfc4f3481167aa205dbe9c5e1","width":400,"height":212}},"href":"https://mma.prnewswire.com/media/2800134/image_5028780_7448517.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"image","alt":"Molecular structure of trastuzumab botidotin (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)","displaySize":"","headline":null,"caption":"Molecular structure of trastuzumab botidotin (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":112,"url":"https://media.zenfs.com/en/prnewswire.com/e9d1564b06e9ff8b2a065e5a50521ed3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UpdUlvwuZbTQr4OWzBmqXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e9d1564b06e9ff8b2a065e5a50521ed3","width":400,"height":112}},"href":"https://mma.prnewswire.com/media/2800135/Molecular_structure_trastuzumab_botidotin.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Trastuzumab botidotin is a HER2-targeted ADC compose...
More updates from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H